Do the signalling-drive route (FGFR/BMP) and the boundary/niche-loss route (TWIST1) converge on an identical osteogenic-acceleration transcriptional program in suture mesenchyme, or do they produce distinct osteoblast states that would respond differently to MAPK-pathway antagonists versus niche/boundary-restoring therapy?
KNOWLEDGE GAP
OPEN
gap_suture_route_convergence_therapy
Attached to:
Loss of Suture Patency Restraint
Cranial Suture Osteogenic Acceleration
The two upstream routes are unified here only at the level of net excess osteoblast differentiation. Whether they share a common effector state determines whether a single therapeutic strategy can address both the signalling-driven (FGFR) and restraint-loss (TWIST1) craniosynostoses.